The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
Open accessAbstract
Histone deacetylases (HDACs) are evolutionary conserved enzymes which operate by removing acetyl groups from histones and other protein regulatory factors, with functional consequences on chromatin remodeling and gene expression profiles. We provide here a review on the recent knowledge accrued on the zinc-dependent HDAC protein family across different species, tissues, and human pathologies, specifically focusing on the role of HDAC inhibitors as anti-cancer agents. We will investigate the chemical specificity of different HDACs and discuss their role in the human interactome as members of chromatin-binding and regulatory complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–318 of 318
Rahmani, M., Aust, M. M., Benson, E. C., Wallace, L. M., Friedberg, J. W., & Grant, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0034 · Cited by 93
Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer
Heers, H. M., Stanislaw, J., Harrelson, J. P., & Lee, M. W. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.057 · Cited by 92
HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1α, and Hsc70
Luo, L., Martin, S. C., Parkington, J. D., Cadena, S. M., Zhu, J., Ibebunjo, C., Summermatter, S., Londraville, N., Patora‐Komisarska, K., Widler, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.023 · Cited by 92
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91
Chu, B. F., Karpenko, M., Liu, Z., Aimiuwu, J., Villalona-Calero, M. A., Chan, K. K. L., Grever, M. R., & Otterson, G. A. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1986-8 · Cited by 90
Stiegler, P., Luca, A. D., Bagella, L., & Giordano, A. (1998) · PubMed · Cited by 89
Zhang, F., Zhang, T., Teng, Z., Zhang, R., Wang, J., & Mei, Q. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8143 · Cited by 89
An Unbiased Approach To Identify Endogenous Substrates of “Histone” Deacetylase 8
Olson, D. E., Udeshi, N. D., Wolfson, N. A., Pitcairn, C. A., Sullivan, E. D., Jaffe, J. D., Svinkina, T., Natoli, T. E., Lü, X., Paulk, J., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500492r · Cited by 89
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Stubbs, M. C., Kim, W.-I., Bariteau, M. A., Davis, T. N., Vempati, S., Minehart, J. C., Witkin, M. D., Qi, J., Krivtsov, A. V., Bradner, J. E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1290 · Cited by 88
Acetylation/Deacetylation Modulates the Stability of DNA Replication Licensing Factor Cdt1
Glozak, M. A., & Seto, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809394200 · Cited by 86
Cao, J., Lv, W., Wang, L., Xu, J., Yuan, P., Huang, S., He, Z., & Hu, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0788-2 · Cited by 86
Zhou, H., Cai, Y., Liu, D., Li, M., Sha, Y., Zhang, W., Wang, K., Gong, J., Tang, N., Huang, A., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12447 · Cited by 85
Moffat, D. F. C., Patel, S. R., Day, F. A., Belfield, A. J., Donald, A., Rowlands, M., Wibawa, J. I. D., Brotherton, D. H., Stimson, L., Clark, V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101177s · Cited by 85
Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 85
Sun, W., Huang, H. F., He, B., Hu, D.-H., Li, P., Yu, Y., Zhou, X., Lv, Z., Zhou, L., Hu, T., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.008 · Cited by 84
Wang, L., Syn, N. L. X., Subhash, V. V., Any, Y., Thuya, W. L., Cheow, E. S. H., Kong, L. R., Yu, F., Peethala, P. C., Wong, A. L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.030 · Cited by 83
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis
Ryu, H.-W., Shin, D.-H., Lee, D. H., Choi, J., Han, G., Lee, K. Y., & Kwon, S. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.033 · Cited by 82
Zhuang, Q., Li, W., Benda, C., Huang, Z., Ahmed, T., Liu, P., Guo, X., Ibañez, D. P., Luo, Z., Zhang, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0047-x · Cited by 81
Mor, N., Rais, Y., Sheban, D., Peles, S., Aguilera-Castrejon, A., Zviran, A., Elinger, D., Viukov, S., Geula, S., Krupalnik, V., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.07.004 · Cited by 79
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0598-5 · Cited by 78
Li, A., Liu, Z., Li, M., Zhou, S., Xu, Y. K., Xiao, Y., & Yang, W. (2016) · Oncotarget · doi:10.18632/oncotarget.9274 · Cited by 78
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
HDAC10 deletion promotes Foxp3+ T-regulatory cell function
Dahiya, S., Beier, U. H., Wang, L., Han, R., Jiao, J., Akimova, T., Angelin, A., Wallace, D. C., & Hancock, W. W. (2020) · Scientific Reports · doi:10.1038/s41598-019-57294-x · Cited by 78
Banerji, U., van Doorn, L., Papadatos-Pastos, D., Kristeleit, R. S., Debnam, P. M., Tall, M., Stewart, A., Raynaud, F. I., Garrett, M. D., Toal, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3165 · Cited by 77
Coni, S., Mancuso, A. B., Di Magno, L., Sdruscia, G., Manni, S., Serrao, S. M., Rotili, D., Spiombi, E., Bufalieri, F., Petroni, M., et al. (2017) · Scientific Reports · doi:10.1038/srep44079 · Cited by 75
Castro, P. G., Roon, E. H. J. V., Pinhanços, S. S., Trentin, L., Schneider, P., Kerstjens, M. J., Kronnie, G. T., Heidenreich, O. T., Pieters, R., & Stam, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.216 · Cited by 75
Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8
Porter, N. J., & Christianson, D. W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00330 · Cited by 74
Histone deacetylase 8 regulates cortactin deacetylation and contraction in smooth muscle tissues
Li, J., Chen, S., Cleary, R. A., Wang, R., Gannon, O. J., Seto, E., & Tang, D. D. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00102.2014 · Cited by 73
Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
Hassell, K. N. (2019) · Diseases · doi:10.3390/diseases7040057 · Cited by 70
Stengel, K. R., & Hiebert, S. W. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5915 · Cited by 69
Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.49 · Cited by 67 · cited 9×
“Low transcript levels of HDAC4 are correlated with a better OS in LGG, pancreatic adenocarcinoma (PAAD) and NBL. Negative staining is showed in lung and renal cancers, while a mild immunoreactivity is observable in stomach, urothelial, testis, and skin cancers.”
BackgroundInfluentialTargeting breast cancer stem cells by novel HDAC3-selective inhibitors
Hsieh, H.-Y., Chuang, H.-C., Shen, F.-H., Detroja, K., Hsin, L.-W., & Chen, C.-S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.069 · Cited by 67
Crabb, S. J., Howell, M., Rogers, H. L., Ishfaq, M., Yurek‐George, A., Carey, K. L., Pickering, B. M., East, P., Mitter, R., Maeda, S., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.004 · Cited by 66
Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors
Das, T. K., Sangodkar, J., Negre, N. N., Narla, G., & Cagan, R. L. (2012) · Oncogene · doi:10.1038/onc.2012.326 · Cited by 65
Torrado, M., Low, J. K. K., Silva, A. P. G., Schmidberger, J. W., Sana, M., Tabar, M. S., Işılak, M. E., Winning, C. S., Kwong, C., Bedward, M. J., et al. (2017) · FEBS Journal · doi:10.1111/febs.14301 · Cited by 65
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2
Xu, P., Ye, S., Li, K., Huang, M., Wang, Q., Zeng, S., Chen, X., Gao, W., Chen, J., Zhang, Q., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1448-9 · Cited by 62
Radhakrishnan, R., Li, Y., Xiang, S., Yuan, F., Yuan, Z., Telles, E., Fang, J., Coppola, D., Shibata, D., Lane, W. S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612945 · Cited by 60
Emerging Roles of Epigenetic Regulator Sin3 in Cancer
Bansal, N., David, G., Farias, E., & Waxman, S. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.006 · Cited by 60
Chien, W., Lee, D. H., Zheng, Y., Wuensche, P., Alvarez, R., Wen, D. L., Aribi, A. M., Thean, S. M., Doan, N., SAID, J. W., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22024 · Cited by 59
Itoh, T., Fairall, L., Muskett, F. W., Milano, C. P., Watson, P. J., Arnaudo, N., Saleh, A., Millard, C. J., El‐Mezgueldi, M., Martino, F., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv068 · Cited by 59
Nettersheim, D., Jostes, S., Fabry, M., Honecker, F. U., Schumacher, V., Kirfel, J., Kristiansen, G., & Schorle, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11647 · Cited by 59
Haydn, T., Metzger, E., Schüle, R., & Fulda, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.239 · Cited by 59
Preclinical anti‐myeloma activity of the novel HDAC‐inhibitor JNJ‐26481585
Stühmer, T., Arts, J., Chatterjee, M., Borawski, J. M., Wolff, A., King, P., Einsele, H., Leo, E., & Bargou, R. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08126.x · Cited by 58
Zhou, L., Chen, S., Zhang, Y., Kmieciak, M., Leng, Y., Li, L., Lin, H., Rizzo, K., Dumur, C. I., Ferreira‐Gonzalez, A., et al. (2016) · Blood · doi:10.1182/blood-2015-06-653717 · Cited by 58
LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation
Nalawansha, D. A., & Pflum, M. K. H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00776 · Cited by 57
MEF2 is regulated by CaMKIIδ2 and a HDAC4–HDAC5 heterodimer in vascular smooth muscle cells
Ginnan, R. G., Sun, L. Y., Schwarz, J. J., & Singer, H. A. (2012) · Biochemical Journal · doi:10.1042/bj20120152 · Cited by 56
Choong, C., Sasaki, T., Hayakawa, H., Yasuda, T., Baba, K., Hirata, Y., Uesato, S., & Mochizuki, H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.001 · Cited by 56
Wheler, J. J., Jankú, F., Falchook, G. S., Jackson, T. L., Fu, S., Naing, A., Tsimberidou, A. M., Moulder, S., Hong, D. S., Yang, H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2384-1 · Cited by 56
HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer
Deng, R., Zhang, P., Liu, W., Zeng, X., Ma, X., Shi, L., Wang, T., Yin, Y., Chang, W., Zhang, P., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0589-6 · Cited by 56
Atsumi, A., Tomita, A., Kiyoi, H., & Naoe, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.047 · Cited by 54
Ahn, M. Y., Kang, D. O., Na, Y. J., Yoon, S., Choi, W. S., Kang, K. W., Chung, H. Y., Jung, J. H., Min, D. S., & Kim, H. S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.017 · Cited by 53
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells
Zhang, L., Bu, L., Hu, J., Xu, Z., Ruan, L., Fang, Y., & Wang, P. (2018) · Biological Chemistry · doi:10.1515/hsz-2017-0306 · Cited by 53
A variant NuRD complex containing PWWP2A/B excludes MBD2/3 to regulate transcription at active genes
Zhang, T., Wei, G., Millard, C. J., Fischer, R., Konietzny, R., Kessler, B. M., Schwabe, J. W. R., & Brockdorff, N. (2018) · Nature Communications · doi:10.1038/s41467-018-06235-9 · Cited by 53
Association of histone deacetylase expression with histology and prognosis of ovarian cancer
Yano, M., Yasuda, M., Sakaki, M., Nagata, K., Fujino, T., Arai, E., Hasebe, T., Miyazawa, M., Miyazawa, M., Ogane, N., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7726 · Cited by 52
Melesina, J., Robaa, D., Pierce, R. J., Romier, C., & Sippl, W. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.10.006 · Cited by 51
Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
Maolanon, A. R., Kristensen, H. M. E., Leman, L. J., Ghadiri, M. R., & Olsen, C. A. (2016) · ChemBioChem · doi:10.1002/cbic.201600519 · Cited by 51
Feng, W., Cai, D., Zhang, B., Lou, G., & Zou, X. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.017 · Cited by 49
Angeletti, F., Fossati, G., Pattarozzi, A., Würth, R., Solari, A., Daga, A., Masiello, I., Barbieri, F., Florio, T., & Comincini, S. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00107 · Cited by 48
Costanzo, A. D., Gaudio, N. D., Conte, L., Dell’Aversana, C., Vermeulen, M., de Thé, H., Migliaccio, A., Nebbioso, A., & Altucci, L. (2018) · Oncogene · doi:10.1038/s41388-018-0143-1 · Cited by 48
Chan, E. W., Chiorean, E. G., O'Dwyer, P. J., Gabrail, N. Y., Alcindor, T., Potvin, D., Chao, R. C., & Hurwitz, H. I. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3494-3 · Cited by 46
Shao, S., Cao, H., Wang, Z., Zhou, D., Wu, C., Wang, S., Xia, D., & Zhang, D. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00827-3 · Cited by 46
The Nuclear Receptor—Co-repressor Complex in Control of Liver Metabolism and Disease
Liang, N., Jakobsson, T., Fan, R., & Treuter, E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00411 · Cited by 44
Wu, L., Wen, Z., Qiu, Y., Chen, X., Chen, H.-B., Wei, M.-M., Liu, Z., Jiang, S., & Zhou, G. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400093y · Cited by 42
Sumoy, L., Carim‐Todd, L., Escarceller, M., Nadal, M., Gratacòs, M., Pujana, M. Á., Estivill, X., & Peral, B. (2000) · Cytogenetic and Genome Research · doi:10.1159/000015486 · Cited by 42
Sin3a regulates epithelial progenitor cell fate during lung development
Yao, C., Carraro, G., Konda, B. M., Guan, X., Mizuno, T., Chiba, N., Kostelny, M., Kurkciyan, A., David, G., McQualter, J. L., et al. (2017) · Development · doi:10.1242/dev.149708 · Cited by 42
Iwahashi, S., Utsunomiya, T., Imura, S., Morine, Y., Ikemoto, T., Arakawa, Y., Saito, Y., Ishikawa, D., & Shimada, M. (2014) · PubMed · Cited by 41
Salvador, L. A., Park, H., Al‐Awadhi, F. H., Liu, Y., Kim, B., Zeller, S. L., Chen, Q.-Y., Hong, J., & Luesch, H. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500170r · Cited by 40
Helland, Ø., Popa, M. L., Bischof, K., Gjertsen, B. T., McCormack, E., & Bjørge, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158208 · Cited by 40
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
Agarwal, S., Milazzo, G., Rajapakshe, K., Bernardi, R. J., Chen, Z., Barbieri, E., Köster, J., Perini, G., Coarfa, C., & Shohet, J. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24859 · Cited by 40
Self-citationDeubzer, H. E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A. E., Schwab, M., & Witt, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.23295 · Cited by 39
Yu, Y., Cao, F., Yu, X., Zhou, P., Di, Q., Lei, J., Tai, Y., Wu, H., Li, X., Wang, X., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1639-9 · Cited by 39
Bürger, M., & Chory, J. (2018) · Communications Biology · doi:10.1038/s42003-018-0214-4 · Cited by 39
Iaconelli, J., Xuan, L. L., & Karmacharya, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071605 · Cited by 38
Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2
Witt, D., Burfeind, P., Hardenberg, S. V., Opitz, L., Salinas, G., Bremmer, F., Schweyer, S., Thelen, P., Neesen, J., & Kaulfuß, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt019 · Cited by 37
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells
Racanicchi, S., Maccherani, C., Liberatore, C., Billi, M., Gelmetti, V., Panigada, M., Rizzo, G., Nervi, C., & Grignani, F. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600593 · Cited by 36
Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer
McLeod, A., Stice, J. P., Wardell, S. E., Alley, H. M., Chang, C., & McDonnell, D. P. (2017) · The Prostate · doi:10.1002/pros.23467 · Cited by 36
Structural basis of the specific interaction of SMRT corepressor with histone deacetylase 4
Park, S., Kim, G. S., Hwang, H.-J., Nam, T.-H., Park, H.-S., Song, J., Jang, T.-H., Lee, Y. C., & Kim, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky926 · Cited by 36
HDAC8 Substrates Identified by Genetically Encoded Active Site Photocrosslinking
López, J. E., Haynes, S. E., Majmudar, J. D., Martin, B. R., & Fierke, C. A. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b07603 · Cited by 35
Ganai, S. A. (2016) · Current Drug Targets · doi:10.2174/1389450117666160527143257 · Cited by 35
Ikeda, M., Ohno, I., Ueno, H., Mitsunaga, S., Hashimoto, Y., Okusaka, T., Kondo, S., Sasaki, M., Sakamoto, Y., Takahashi, H., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0634-5 · Cited by 35
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
Lehmann, M., Hoffmann, M. J., Koch, A., Ulrich, S. M., Schulz, W. A., & Niegisch, G. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-014-0059-8 · Cited by 34 · cited 21×
“For example, HDAC1 decrotonylates H3K4cr, H3K9cr, H3K23cr, H4K8cr, and H4K12cr in vitro; H3K8cr can be also decrotonylated by HDAC2 and HDAC8.”
BackgroundInfluentialThe antitumor effects of entinostat in ovarian cancer require adaptive immunity
Smith, H. J., McCaw, T. R., Londoño, A. I., Katre, A. A., Meza‐Perez, S., Yang, E. S.-H., Forero, A., Buchsbaum, D. J., Randall, T. D., Straughn, J. M., et al. (2018) · Cancer · doi:10.1002/cncr.31761 · Cited by 34
McClellan, D., Casey, M. J., Bareyan, D., Lucente, H., Ours, C., Velinder, M., Singer, J., Lone, M. D., Sun, W., Coria, Y., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00020-19 · Cited by 32
Histone deacetylase complexes as caretakers of genome stability
Lahue, R. S., & Frizzell, A. (2012) · Epigenetics · doi:10.4161/epi.20922 · Cited by 31
Amengual, J. E., Prabhu, S. A., Lombardo, M., Zullo, K. M., Johannet, P. M., Gonzalez, Y., Scotto, L., Serrano, X. O. J., Wei, Y., Duong, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2022 · Cited by 30
Molecular cloning of Drosophila melanogaster cDNAs that encode a novel histone deacetylase dHDAC3
Johnson, C. A., Barlow, A. L., & Turner, B. M. (1998) · Gene · doi:10.1016/s0378-1119(98)00435-1 · Cited by 29
Sholler, G. L. S., Currier, E. A., Dutta, A., Slavik, M. A., Illenye, S., Mendonça, M. C., Dragon, J. A., Roberts, S. S., & Bond, J. P. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-21 · Cited by 29
Stengel, K. R., Barnett, K. R., Wang, J., Liu, Q., Hodges, E. C., Hiebert, S. W., & Bhaskara, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701610114 · Cited by 29
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells
Flis, S., Gnyszka, A., Flis, K., & Splawinski, J. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.033 · Cited by 28
Targeting the GFI1/1B—CoREST Complex in Acute Myeloid Leukemia
van Bergen, M. G. J. M., & van der Reijden, B. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01027 · Cited by 28
Metabolic Homeostasis: HDACs Take Center Stage
Karpac, J., & Jasper, H. (2011) · Cell · doi:10.1016/j.cell.2011.04.017 · Cited by 27
HDAC1 Substrate Profiling Using Proteomics-Based Substrate Trapping
Nalawansha, D. A., Zhang, Y., Herath, K. E., & Pflum, M. K. H. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00737 · Cited by 27
Cheng, Y., Liao, L., Yang, Q., Chen, Y., Nie, P., Zhang, X., Xie, J., Shan, B., Zhao, L., Xu, L., et al. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3359 · Cited by 26
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
Bose, P., Swaminathan, M., Pemmaraju, N., Ferrajoli, A., Jabbour, E. J., Daver, N. G., Dinardo, C. D., Alvarado, Y., Yilmaz, M. E., Huynh-Lu, J., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1543876 · Cited by 26
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis
Muscolini, M., Castiello, L., Palermo, E., Zevini, A., Ferrari, M., Olagnier, D. P., & Hiscott, J. B. (2019) · Journal of Virology · doi:10.1128/jvi.00626-19 · Cited by 26
Pilon, J. L., Clausen, D. J., Hansen, R. J., Lunghofer, P. J., Charles, B., Rose, B. J., Thamm, D. H., Gustafson, D. L., Bradner, J. E., & Williams, R. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2675-1 · Cited by 25
Bhalla, S., Evens, A. M., Prachand, S., Schumacker, P. T., & Gordon, L. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081333 · Cited by 24
A novel yeast histone deacetylase: Partial characterization and development of an activity assay
Alonso, W. R., & Nelson, D. A. (1986) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(86)90113-2 · Cited by 23
Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Cheng, K., Li, S., & Liao, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170209105315 · Cited by 23
Pan-Cancer and Single-Cell Modeling of Genomic Alterations Through Gene Expression
Mercatelli, D., Ray, F., & Giorgi, F. M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00671 · Cited by 23
Self-citationSystematic identification of Class I HDAC substrates
Li, T., Song, B., Wu, Z., Lu, M., & Zhu, W. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbt060 · Cited by 21
Li, Y., Zhao, K., Yao, C., Kahwash, S. B., Tang, Y., Zhang, G., Patterson, K., Wang, Q., & Zhao, W. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.117 · Cited by 21
DiMauro, T., Cantor, D. J., Bainor, A. J., & David, G. (2014) · Oncogene · doi:10.1038/onc.2014.322 · Cited by 20
AcuC, a histone deacetylase, contributes to the pathogenicity of Aeromonas hydrophila
Jiang, Q., Chen, W., Qin, Y., Huang, L., Xu, X., Zhao, L., & Yan, Q. (2017) · MicrobiologyOpen · doi:10.1002/mbo3.468 · Cited by 20
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
Human Histone Deacetylase 2,HDAC2(HumanRPD3), Is Localized to 6q21 by Radiation Hybrid Mapping
Betz, R. C., Gray, S. G., Ekström, C., Larsson, C., & Ekström, T. J. (1998) · Genomics · doi:10.1006/geno.1998.5435 · Cited by 19
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
Lopez, G., Braggio, D., Zewdu, A., Casadei, L., Batte, K., Bid, H. K., Koller, D., Yu, P., Iwenofu, O. H., Strohecker, A. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188859 · Cited by 17
Pinazza, M., Borga, C., Agnusdei, V., Minuzzo, S. A., Fossati, G., Paganin, M., Michielotto, B., Paoli, A. D., Basso, G., Amadori, A., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.394 · Cited by 16
Tambo, Y., Hosomi, Y., Sakai, H., Nogami, N., Atagi, S., Sasaki, Y., Kato, T., Takahashi, T., Seto, T., Maemondo, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0435-2 · Cited by 16
Choi, K. Y., Ji, Y. J., Jee, C., Kim, D. H., & Ahnn, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00374-1 · Cited by 15
Park, H., Kim, Y., Park, D., & Jeoung, D. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.6.169 · Cited by 15
Smith, E. M. K., Zhang, L., Walker, B. A., Davenport, E. L., Aronson, L. I., Krige, D., Hooftman, L. W., Drummond, A. H., Morgan, G. J., & Davies, F. E. (2013) · Oncotarget · doi:10.18632/oncotarget.1168 · Cited by 13
Shimizu, H., Lu, Y., Vella, K. R., Damilano, F., Astapova, I. I., Amano, I., Ritter, M. J., Gallop, M. R., Rosenzweig, A. N., Cohen, R., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220717 · Cited by 13
Min, K. N., Cho, M. J., Kim, D., & Sheen, Y. Y. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02980131 · Cited by 10
Electron cryo-microscopy for elucidating the dynamic nature of live-protein complexes
Shigematsu, H. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.129436 · Cited by 9
Network of phosphatases and HDAC complexes at repressed chromatin
de Castro, I. J., Amin, H. A., Vinciotti, V., & Vagnarelli, P. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1371883 · Cited by 7
Effect of histone deacetylase on prostate carcinoma.
Zhang, Y., Xu, Q., Liu, G., Huang, H., Lin, W., Huang, Y., Chi, Z., Chen, S., Lan, K., Lin, J., et al. (2015) · PubMed Central · Cited by 4
Zalloum, W. A., & Zalloum, H. M. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00256 · Cited by 4
Cited by
Zhu, S., Chen, W., Masson, A., & Li, Y.-P. (2024) · Cell Discovery · doi:10.1038/s41421-024-00689-6 · Cited by 463
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
Bahl, S., & Seto, E. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03599-4 · Cited by 82
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Metadata
- Authors
- Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2020-05-15
- Volume
- 11
- Issue
- 5
- Pages
- 556
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W3024404242
- Cited by
- 423
- References
- 318
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.